{
    "clinical_study": {
        "@rank": "42107", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating\n      patients who have stage IIIB or stage IV non-small cell lung cancer."
        }, 
        "brief_title": "Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer", 
        "condition": "Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the response rate and duration of response to mitomycin, vinorelbine, and\n           cisplatin plus tretinoin in patients with stage IIIB or IV non-small cell lung cancer.\n\n        -  Determine the toxicity of this treatment regimen in these patients.\n\n        -  Determine survival of these patients with this treatment regimen.\n\n      OUTLINE: Patients receive tretinoin orally twice daily for 4 days starting days 1 and 8;\n      cisplatin IV over 2 hours and vinorelbine IV on days 1 and 8; and mitomycin IV (courses 1\n      and 3) on day 1. Treatment repeats every 3 weeks in the absence of disease progression or\n      unacceptable toxicity.\n\n      Patients are followed for survival.\n\n      PROJECTED ACCRUAL: At total of 15-46 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed stage IIIB or IV non-small cell lung cancer\n\n          -  Measurable disease\n\n          -  No brain metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Over 18\n\n        Performance status:\n\n          -  Zubrod 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Absolute granulocyte count greater than 2,000/mm^3\n\n          -  Platelet count greater than 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin less than 2 times upper limit of normal (ULN)\n\n          -  AST and ALT less than 2.5 times ULN (unless attributed to liver metastases)\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 mg/dL AND/OR\n\n          -  Creatinine clearance at least 60 mL/min\n\n        Cardiovascular:\n\n          -  No myocardial infarction within past 6 months\n\n          -  No congestive heart failure\n\n          -  No uncontrolled arrhythmia\n\n        Other:\n\n          -  No other concurrent or prior malignancy within past 5 years except localized basal\n             cell or squamous cell skin cancer\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  HIV negative\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  No prior chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy with clearly progressive disease\n\n          -  Concurrent palliative radiotherapy allowed if no evidence of disease progression\n\n        Surgery:\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "June 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005825", 
            "org_study_id": "CDR0000067837", 
            "secondary_id": [
                "NANDAN-VES-024", 
                "NCI-V00-1587"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "mitomycin C", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "tretinoin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "vinorelbine tartrate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mitomycins", 
                "Mitomycin", 
                "Vinorelbine", 
                "Cisplatin", 
                "Tretinoin", 
                "Vinblastine"
            ]
        }, 
        "keyword": [
            "stage IIIB non-small cell lung cancer", 
            "stage IV non-small cell lung cancer"
        ], 
        "lastchanged_date": "December 17, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/NANDAN-VES-024"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Lakewood", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90712"
                }, 
                "name": "Rajendra Prasad M.D., Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Trans Retinoic Acid (Vesanoid) With Chemotherapy in Non-Small Cell Lung Cancer", 
        "overall_official": {
            "affiliation": "Raghu Nandan, M.D., Inc", 
            "last_name": "Raghu Nandan, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005825"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Raghu Nandan, M.D., Inc", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 1998", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2003"
    }, 
    "geocoordinates": {
        "Rajendra Prasad M.D., Inc.": "33.854 -118.134"
    }
}